건염 치료 시장 : 치료법, 용도, 유통 채널, 최종 용도별 - 세계 예측(2024-2032년)

Global Tendonitis Treatment Market will witness 3.8% CAGR between 2024 and 2032, fueled by increasing research and development efforts from leading companies. With tendonitis being a prevalent condition affecting millions globally, there is a growing need for innovative treatments that offer effective relief and faster recovery.

For instance, in June 2023, Physical medicine and rehabilitation specialists at Mayo Clinic are utilizing ultrasound guidance for percutaneous tenotomies, employing a high-pressure saline stream to treat individuals with chronic tendinopathy. Referred to as percutaneous pressured hydrotenotomy, this outpatient procedure did not necessitate general anesthesia.

Leading pharmaceutical and biotech companies are investing heavily in R&D to develop novel therapies, including regenerative medicine approaches and advanced drug formulations. Additionally, technological advancements such as wearable devices and minimally invasive procedures are reshaping the landscape of tendonitis treatment. As these efforts yield promising results, the market for tendonitis treatments is poised for significant growth, offering hope for patients and driving the evolution of healthcare solutions tailored to address this common ailment.

The overall Tendonitis Treatment Industry is classified based on the treatment, application, distribution channel, end-use, and region.

The surgery segment will undergo notable development from 2024 to 2032. Surgery remains a crucial option for patients with severe or refractory tendonitis cases, particularly when conservative treatments fail to provide relief. Procedures such as percutaneous tenotomies or tendon repairs offer effective solutions for restoring tendon function and alleviating symptoms. With advancements in minimally invasive techniques and improved surgical outcomes, there is a growing preference for surgical treatments among patients and healthcare providers. As a result, the demand for surgical interventions in the tendonitis treatment market continues to expand, addressing the needs of individuals seeking long-term relief and improved quality of life.

The tendonitis treatment market share from the supraspinatus tendonitis segment will register a noteworthy CAGR from 2024 to 2032. As a common cause of shoulder pain, supraspinatus tendinitis requires effective treatment options to alleviate discomfort and restore function. Both conservative approaches, such as rest, physical therapy, and NSAIDs, as well as more advanced treatments, including corticosteroid injections or surgical interventions, are sought to address this condition. To reduce pain and improve shoulder mobility, the demand for innovative and tailored treatments targeting supraspinatus tendinitis remains high in the tendonitis treatment market.

Asia Pacific tendonitis treatment market will showcase a commendable CAGR from 2024 to 2032. With a large population and increasing prevalence of tendonitis-related conditions due to aging, physical activity, and occupational hazards, there is a growing need for effective treatment options. Moreover, rising healthcare awareness, improving access to medical facilities, and advancements in treatment modalities contribute to the expanding market demand. As healthcare infrastructure continues to develop across the Asia-Pacific region, the demand for tendonitis treatments could rise steadily to meet the needs of the growing population. For instance, in March 2024, a Chinese research group led by the Shanghai Institute of Ceramics of the Chinese Academy of Sciences devised a multicellular scaffold using inorganic bioceramics to address tendon-to-bone injuries.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of sports related injuries
    • 3.2.1.2 Rising incidence of bone related disorders
    • 3.2.1.3 Growing technological advancements
    • 3.2.1.4 Increasing awareness regarding physical fitness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Inflated of cost of tendonitis treatment
    • 3.2.2.2 Lack of reimbursement scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Therapy
  • 5.2.1 Hot & cold therapy
  • 5.2.2 Physical therapy
  • 5.2.3 Shockwave therapy
• 5.3 Surgery
• 5.4 Medications
  • 5.4.1 Oral
  • 5.4.2 Topical

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Achilles tendonitis
• 6.3 Supraspinatus tendonitis
• 6.4 Tennis elbow
• 6.5 Pitcher's elbow
• 6.6 Jumper's knee

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Home care settings
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AstraZeneca
• 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
• 10.4 Bristol Myers Squibb Company
• 10.5 Colfax Corporation
• 10.6 GalxoSmithKline AG
• 10.7 Johnson & Johnson
• 10.8 Merck and Co., Inc.
• 10.9 Ossur
• 10.10 Pifzer Inc.
• 10.11 Stryker Corporation
• 10.12 Teva Pharmaceutical Industries Ltd.
• 10.13 Tynor Orthotics Pvt. Ltd
• 10.14 Zimmer Biomet Holdings, Inc.